- Home
- CEE vs FATE Comparison
CEE vs FATE Comparison
Compare CEE & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | FATE |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 139.6M |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CEE | FATE |
|---|---|---|
| Price | $18.33 | $1.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 19.2K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.20 | $0.66 |
| 52 Week High | $19.98 | $1.94 |
Technical Indicators
Market Signals| Indicator | CEE | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 41.89 |
| Support Level | $16.95 | $0.96 |
| Resistance Level | $18.35 | $1.35 |
| Average True Range (ATR) | 0.60 | 0.12 |
| MACD | -0.17 | -0.04 |
| Stochastic Oscillator | 27.90 | 1.96 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.